Top

Published in:

01-02-2007 | Therapy in Practice

Monitoring the Safe Use of Clozapine

A Consensus View from Victoria, Australia

Authors: Michael Berk, Joanna Fitzsimons, Timothy Lambert, Christos Pantelis, Jayashri Kulkarni, David Castle, Elizabeth W. Ryan, Sean Jespersen, Pat McGorry, Gregor Berger, Bill Kuluris, Tom Callaly, Dr Seetal Dodd

Published in: CNS Drugs | Issue 2/2007

Abstract

Clozapine is an important antipsychotic agent that has a unique profile of clinical benefits, but that has also been associated with several serious and potentially life-threatening safety concerns. In order to minimise the impact of haematological adverse events, health professionals treating patients with clozapine are currently required to register their patients on a centrally administered data network and to conform to strict protocols. The consensus statement documented in this article extends existing protocols by recommending monitoring of patients treated with clozapine for additional adverse effects during treatment. This consensus statement reflects the current practice at five major public psychiatric hospitals in Victoria, Australia, for the monitoring and management of clozapine-related adverse events, and has been implemented at these sites because of emerging safety concerns associating clozapine with cardiovascular and metabolic adverse effects.

Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9): 789–96PubMedCrossRef

Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151(12): 1744–52PubMed

Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50(9): 329–38PubMed

Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59Suppl. 3: 3–7PubMed

Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329(3): 162–7PubMedCrossRef

Clozaril (clozapine) tablets. Briefing book for Psychopharmacological Drugs Advisory Committee Meeting (2003 Jun 16). East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2003

Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996; 47(1): 52–6PubMed

Stubner S, Grohmann R, Engel R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37Suppl. 1: S70–8PubMed

Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994. 55Suppl B: 137–8PubMed

10.

Hummer M, Kurz M, Barnas C, et al. Clozapine-induced transient white blood count disorders. J Clin Psychiatry 1994; 55(10): 429–32PubMed

11.

Lieberman JA, Alvir JM. A report of clozapine-induced agranulocytosis in the United States: incidence and risk factors. Drug Saf 1992; 7Suppl. 1: 1–2PubMedCrossRef

12.

Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55Suppl. B: 139–42PubMed

13.

Pantelis C, Adesanya A. Increased risk of neutropenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z J Psychiatry 2001; 35(4): 544–5PubMedCrossRef

14.

Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993; 54(12): 466–9PubMed

15.

Chatterton R. Eosinophilia after commencement of clozapine treatment. Aust N Z J Psychiatry 1997; 31(6): 874–6PubMedCrossRef

16.

Conus P, Nanzer N, Baumann P. An alternative to interruption of treatment in recurrent clozapine-induced severe neutropenia [letter]. Br J Psychiatry 2001; 179: 180PubMedCrossRef

17.

Clopine (clozapine). Connect™ protocol. Melbourne (VIC): Mayne Pharma, 2004

18.

Young CR, Bowers Jr MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24(3): 381–90PubMedCrossRef

19.

Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology (Berl) 1989; 99 Suppl.: S118–21CrossRef

20.

Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255–63PubMedCrossRef

21.

Sperner-Unterweger B, Czeipek I, Gaggl S, et al. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF): remission despite continuous treatment with clozapine. Br J Psychiatry 1998; 172: 82–4PubMedCrossRef

22.

Hagg S, Rosenius S, Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. Int Clin Psychopharmacol 2003; 18(3): 173–4PubMedCrossRef

23.

Lambert TJ, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181(10): 544–8PubMed

24.

Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70(1): 1–17PubMedCrossRef

25.

Sumiyoshi T, Roy A, Anil AE, et al. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol 2004; 24(3): 345–8PubMedCrossRef

26.

Miller MJ, Molla PM. Prevalence of diabetes mellitus in patients receiving depot neuroleptics or clozapine. Arch Psychiatr Nurs 2005; 19(1): 30–4PubMedCrossRef

27.

Hagg S, Joelsson L, Mjorndal T, et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with lozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59(6): 294–9PubMedCrossRef

28.

Lindenmayer JP, CZobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160(2): 290–6PubMedCrossRef

29.

Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157(6): 975–81PubMedCrossRef

30.

Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59(4): 337–45PubMedCrossRef

31.

Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63(10): 856–65PubMedCrossRef

32.

Wilson DR, D’Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003; 9(1): 1–6CrossRef

33.

Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes: findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care 2002; 25(10): 1722–8PubMedCrossRef

34.

Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156(8): 1270–2PubMed

35.

Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002; 71(3): 239–57PubMedCrossRef

36.

Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004; 6(4): 314–8PubMedCrossRef

37.

Cohn T, Prud’homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49(11): 753–60PubMed

38.

Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64(5): 575–9PubMedCrossRef

39.

Association of clozaril (clozapine) with cardiovascular toxicity (Dear Healthcare Professional letter). Ottawa (ON): Novartis Pharma Canada Inc., 2002

40.

Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61(6): 441–6PubMedCrossRef

41.

Pantelis C, Soulsby B, Harrison B, et al. Echocardiographic changes associated with clozapine in treatment-resistant schizophrenia [abstract]. Schizophrenia Res 2001; 49(2 Suppl. 1): 289

42.

Marinkovic D, Timotijevic I, Babinski T, et al. The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(3): 537–44PubMedCrossRef

43.

Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58(12): 1172–6PubMedCrossRef

44.

Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322(7296): 1207–9PubMedCrossRef

45.

Killian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354(9193): 1841–5CrossRef

46.

La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001; 345(3): 224–5PubMedCrossRef

47.

Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in colloboration with the American Society of Echocardiography. Circulation 1997; 95(6): 1686–744

48.

Marder SR, Essock SM, Miller AL, et al. Physical health onitoring of patients with schizophrenia. Am J Psychiatry 2004; 161(8): 1334–49PubMedCrossRef

49.

Bell R, McLaren A, Galanos J, et al. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 1998; 32(4): 567–74PubMedCrossRef

50.

Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148(2): 231–5PubMed

51.

Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994; 55Suppl. B: 117–21PubMed

52.

Llorca PM, Lancon C, Disdier B, et al. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci 2002; 27(1): 30–7PubMed

53.

VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153(12): 1579–84PubMed

54.

Kurz M, Hummer M, Kemmler G, et al. Long-term pharmacokinetics of clozapine. Br J Psychiatry 1998; 173: 341–4PubMedCrossRef

55.

Lieberman JA, Johns CA, Kane JM, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988; 49(7): 271–7PubMed

56.

Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 1997; 32(2): 93–100PubMedCrossRef

57.

Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37(6): 243–65PubMedCrossRef

58.

Humme M, Kurz M, Kurzthaler I, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997; 17(4): 314–7CrossRef

59.

Macfarlane B, Davies S, Mannan K, et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112(5): 1707–9PubMedCrossRef

60.

Taylor D, Paton C, Kerwin R. The Maudsley prescribing guidelines. 7th ed. London: Martin Dunitz, 2003

61.

Erdogan A, Kocabasoglu N, Yalug I, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 2004; 34(1): 83–9PubMedCrossRef

62.

Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003; 178 Suppl.: S67–70PubMed

63.

McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534–9PubMedCrossRef

64.

Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66(9): 1116–21PubMedCrossRef

Title: Monitoring the Safe Use of Clozapine
A Consensus View from Victoria, Australia
Authors: Michael Berk
Joanna Fitzsimons
Timothy Lambert
Christos Pantelis
Jayashri Kulkarni
David Castle
Elizabeth W. Ryan
Sean Jespersen
Pat McGorry
Gregor Berger
Bill Kuluris
Tom Callaly
Dr Seetal Dodd
Publication date: 01-02-2007
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 2/2007
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200721020-00003

At a glance: The STEP trials

Springer Medicine

Monitoring the Safe Use of Clozapine

A Consensus View from Victoria, Australia

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Spectral Frequency Index Monitoring During Propofol-Remifentanil and Propofol-Alfentanil Total Intravenous Anaesthesia

Pharmacological Treatment of the Psychosis of Alzheimer’s Disease

Spotlight on Methylphenidate Controlled-Delivery Capsules(Equasym™XL, Metadate CD™) in the Treatment of Children and Adolescents with Attention-Deficit Hyperactivity Disorder

Treatment Strategies After a Single Seizure

Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy

Lack of Insight in Schizophrenia